The study of effectiveness of systemic Magnesium in treatment of sudden sensory neural hearing loss versus placebo

The study of effectiveness of systemic Magnesium in treatment of sudden sensory neural hearing loss versus placebo in patient referred to ear nose and throat clinic of Taleqani hospital.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200430047245N1

Enrollment

Registered

2021-05-23

Start date

2021-04-24

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sudden sensory nueral hearing loss. Sudden idiopathic hearing loss

Interventions

Intervention 1: Intervention group: In this group, patients with sensorineural hearing loss undergo standard treatment with oral corticosteroids at a dose of 1 mg per kg body weight per day with 50 mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Affection to sudden sensory neural hearing loss The reason of sudden sensory neural hearing loss be idiopathic

Exclusion criteria

Exclusion criteria: Referral after 1 month from the onset of the disease Contraindications to oral corticosteroids such as diabetes, hypertension, gastric ulcer or duodenum Evidence of systemic infectious or inflammatory diseases Coagulation disorders Other known causes of sudden sensory neural hearing loss

Design outcomes

Primary

Measure	Time frame
Average hearing threshold. Timepoint: Mean hearing threshold before the start of the study and 14 days after the intervention and the end of the month. Method of measurement: Audiometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Taha Mehdi Araghi

Shahid Beheshti University of Medical Sciences

tahamehdiaraghi1990@gmail.com+98 21 2303 1111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026